CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

PURPOSE: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. PATIENTS AND METHODS: CD33 ex...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Pollard, Jessica A., Loken, Michael, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Aplenc, Richard, Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2016
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872025/
https://ncbi.nlm.nih.gov/pubmed/26786921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.6846
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi